The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to pri... by Fox, S, Generali, D, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Mele, T, Dogliotti, L, Bottini, A, Harris, A

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. by Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients by Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to pri... by Fox, S, Generali, D, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Mele, T, Dogliotti, L, Bottini, A, Harris, A

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer by Generali, D, Fox, S, Berruti, A, Moore, J, Brizzi, M, Patel, N, Allevi, G, Bonardi, S, Aguggini, S, Bersiga, A, Campo, L, Dogliotti, L, Bottini, A, Harris, A

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. by Generali, D, Fox, S, Berruti, A, Moore, J, Brizzi, M, Patel, N, Allevi, G, Bonardi, S, Aguggini, S, Bersiga, A, Campo, L, Dogliotti, L, Bottini, A, Harris, A

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. by Generali, D, Buffa, F, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Papotti, M, Dogliotti, L, Bottini, A, Harris, A, Fox, S

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. by Generali, D, Bates, G, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Dogliotti, L, Banham, A, Harris, A, Bottini, A, Fox, S

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. by Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A

P157 MammaPrint 8-year follow up results in patients with early breast cancer from a single-center Italian cohort study by E. Fiorino, F. Giudici, S. Aguggini, C. Strina, M. Milani, N. Ziglioli, M. Dester, G. Barbieri, M. Alberio, C. Azzini, G. Ferrero, M. Ungari, C. Dreezen, D. Pronin, D. Generali

Get full text

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. by Generali, D, Fox, S, Brizzi, M, Allevi, G, Bonardi, S, Aguggini, S, Milani, M, Bersiga, A, Campo, L, Dionisio, R, Vergoni, F, Giardini, R, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer by Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, MR, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S, Harris, A, Bottini, A, Berruti, A, Generali, D

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. by Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, MR, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S, Harris, A, Bottini, A, Berruti, A, Generali, D

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment by A Ianza, F Giudici, C Pinello, SP Corona, C Strina, O Bernocchi, M Bortul, M Milani, M Sirico, G Allevi, S Aguggini, A Cocconi, C Azzini, M Dester, V Cervoni, A Bottini, M Cappelletti, D Generali

Get full text

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer by Andreis, D, Bonardi, S, Allevi, G, Aguggini, S, Gussago, F, Milani, M, Strina, C, Spada, D, Ferrero, G, Ungari, M, Rocca, A, Nanni, O, Roviello, G, Berruti, A, Harris, A, Fox, S, Roviello, F, Polom, K, Bottini, A, Generali, D

Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib by Francesco Schettini, Maria Valeria De Bonis, Carla Strina, Manuela Milani, Nicoletta Ziglioli, Sergio Aguggini, Ignazio Ciliberto, Carlo Azzini, Giuseppina Barbieri, Valeria Cervoni, Maria Rosa Cappelletti, Giuseppina Ferrero, Marco Ungari, Mariavittoria Locci, Ida Paris, Giovanni Scambia, Gianpaolo Ruocco, Daniele Generali

Get full text

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial by Francesco Schettini, Francesco Schettini, Silvia Paola Corona, Silvia Paola Corona, Fabiola Giudici, Fabiola Giudici, Carla Strina, Marianna Sirico, Ottavia Bernocchi, Ottavia Bernocchi, Manuela Milani, Nicoletta Ziglioli, Sergio Aguggini, Carlo Azzini, Giuseppina Barbieri, Valeria Cervoni, Maria Rosa Cappelletti, Alfredo Molteni, Maria Chiara Lazzari, Giuseppina Ferrero, Marco Ungari, Elena Marasco, Alice Bruson, Luciano Xumerle, Elisa Zago, Davide Cerra, Marco Loddo, Gareth H. Williams, Ida Paris, Ida Paris, Giovanni Scambia, Giovanni Scambia, Daniele Generali, Daniele Generali

Get full text